# EDGAR Filing Document

**Accession Number:** 0001187333
**File Stem:** 0001187333-26-000002
**Filing Date:** 2026-4
**Character Count:** 9777
**Document Hash:** 02f91e5fa1089885826dee9bc9670af7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001187333-26-000002.hdr.sgml**: 20260422

**ACCESSION NUMBER**: 0001187333-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260420

**FILED AS OF DATE**: 20260422

**DATE AS OF CHANGE**: 20260422

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** RENTON HOLLINGS
- **CENTRAL INDEX KEY:** 0001187333

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37985
- **FILM NUMBER:** 26885023

**MAIL ADDRESS:**
- **STREET 1:** 10421 PACIFIC CENTER COURT
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ANAPTYSBIO, INC
- **CENTRAL INDEX KEY:** 0001370053
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 203828755
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE, SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-362-6295

**MAIL ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE, SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANAPTYSBIO INC
- **DATE OF NAME CHANGE:** 20080828

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANAPTYS BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20060724

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>RENTON HOLLINGS<br><sub>(Last) (First) (Middle)</sub><br>C/O ANAPTYSBIO, INC.<br>10770 WATERIDGE CIRCLE, SUITE 210<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ANAPTYSBIO, INC [ ANAB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $24.60 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 15000 | <sup>(2)</sup> | 2027-02-23 | Common Stock | 15000 | $0 | 15000 | D |  |
| Stock Option (right to buy) | $18.03 | 2026-04-20 |  | A<sup>(1)</sup> |  | 15000 |  | <sup>(2)</sup> | 2027-02-23 | Common Stock | 15000 | $0 | 15000 | D |  |
| Stock Option (right to buy) | $104.81 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 6000 | <sup>(2)</sup> | 2028-02-01 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $76.79 | 2026-04-20 |  | A<sup>(1)</sup> |  | 6000 |  | <sup>(2)</sup> | 2028-02-01 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $68.88 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 6000 | <sup>(2)</sup> | 2029-02-07 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $50.47 | 2026-04-20 |  | A<sup>(1)</sup> |  | 6000 |  | <sup>(2)</sup> | 2029-02-07 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $16.56 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 11000 | <sup>(2)</sup> | 2030-02-11 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $12.14 | 2026-04-20 |  | A<sup>(1)</sup> |  | 11000 |  | <sup>(2)</sup> | 2030-02-11 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $29.70 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 11000 | <sup>(2)</sup> | 2031-02-09 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $21.76 | 2026-04-20 |  | A<sup>(1)</sup> |  | 11000 |  | <sup>(2)</sup> | 2031-02-09 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $30.44 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 9200 | <sup>(2)</sup> | 2032-02-09 | Common Stock | 9200 | $0 | 9200 | D |  |
| Stock Option (right to buy) | $22.13 | 2026-04-20 |  | A<sup>(1)</sup> |  | 9200 |  | <sup>(2)</sup> | 2032-02-09 | Common Stock | 9200 | $0 | 9200 | D |  |
| Stock Option (right to buy) | $23.23 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 10600 | <sup>(2)</sup> | 2033-01-05 | Common Stock | 10600 | $0 | 10600 | D |  |
| Stock Option (right to buy) | $17.02 | 2026-04-20 |  | A<sup>(1)</sup> |  | 10600 |  | <sup>(2)</sup> | 2033-01-05 | Common Stock | 10600 | $0 | 10600 | D |  |
| Stock Option (right to buy) | $21.19 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 16510 | <sup>(2)</sup> | 2034-01-02 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $15.53 | 2026-04-20 |  | A<sup>(1)</sup> |  | 16510 |  | <sup>(2)</sup> | 2034-01-02 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $14.83 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 16510 | <sup>(2)</sup> | 2035-01-06 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $10.87 | 2026-04-20 |  | A<sup>(1)</sup> |  | 16510 |  | <sup>(2)</sup> | 2035-01-06 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $43.91 | 2026-04-20 |  | D<sup>(1)</sup> |  |  | 5500 | <sup>(3)</sup> | 2036-01-06 | Common Stock | 5500 | $0 | 5500 | D |  |
| Stock Option (right to buy) | $32.17 | 2026-04-20 |  | A<sup>(1)</sup> |  | 5500 |  | <sup>(3)</sup> | 2036-01-06 | Common Stock | 5500 | $0 | 5500 | D |  |

---

### Footnotes:

(1) Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.

(2) The stock option is fully vested and exercisable.

(3) The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

**Signature:** /s/ Dan Faga, Attorney-in-Fact  
**Date:** 2026-04-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**